KYMR NASDAQ
Watertown, MA 02472
US
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Esposito Pamela | M-Exempt | 1,000 | $31.20 | 2026-05-19 |
| Esposito Pamela | M-Exempt | 1,000 | $31.20 | 2026-05-19 |
| Jacobs Bruce N. | M-Exempt | 15,000 | $2.08 | 2026-05-18 |
| Jacobs Bruce N. | M-Exempt | 15,000 | $2.08 | 2026-05-18 |
| Ridloff Elena | M-Exempt | 3,000 | $31.20 | 2026-05-11 |